Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals · 2025
Combined plasma levels of A-type-natriuretic peptide and adrenomedullin are associated with appropriate anti-arrhythmia therapy in patients with an implantable cardioverter defibrillator but no prior device therapy.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Beygui Farzin, Roule Vincent, Gandjbakhch Estelle, Ollitrault Pierre, Silvain Johanne, Milliez Paul, Vignolles Nicolas, Zeitouni Michel, Guedeney Paul, Champ-Rigot Laure, Blanchart Katrien, Montalescot Gilles
Аннотация
BACKGROUND: Identifying patients benefiting from implantable cardioverter defibrillators (ICD) especially when replacing one that has never served may be challenging.
OBJECTIVES: We assessed the association between plasma levels of mid-regional-pro-A-type-natriuretic peptide (ANP), Mid-regional-pro-adrenomedullin (ADM) and aldosterone and, appropriate Implantable Cardioverter Defibrillator (ICD)-therapy in patients with an ICD but no prior therapy.
METHODS: A cohort of 331 consecutive patients with an ICD but no prior ICD-therapy was prospectively included in 2 centers and followed-up for a median of 7.9 years. Plasma aldosterone, ANP and ADM levels were measured at inclusion. The primary outcome was the occurrence of appropriate ICD-therapy.
RESULTS: Appropriate ICD-therapy and death occurred in 106(32%) and 114(34%) patients respectively. Rates of ICD generator replacement were 62% regardless of ICD-therapy. The multivariable model showed significant relationships between ANP > median (adjusted HR 1.73[95% CI 1.04-2.86]) and ADM > median (HR 0.53 [95% CI 0.32-0.89]) but not aldosterone, and ICD-therapy. The Fine and Gray analysis accounting mortality as a competing risk showed similar results.
CONCLUSIONS: The combination of ANP and ADM are independently associated with the risk of ICD-therapy in patients with an ICD that has never served, and may participate in stratifying patients who may benefit most from ICD generator replacement.
OBJECTIVES: We assessed the association between plasma levels of mid-regional-pro-A-type-natriuretic peptide (ANP), Mid-regional-pro-adrenomedullin (ADM) and aldosterone and, appropriate Implantable Cardioverter Defibrillator (ICD)-therapy in patients with an ICD but no prior therapy.
METHODS: A cohort of 331 consecutive patients with an ICD but no prior ICD-therapy was prospectively included in 2 centers and followed-up for a median of 7.9 years. Plasma aldosterone, ANP and ADM levels were measured at inclusion. The primary outcome was the occurrence of appropriate ICD-therapy.
RESULTS: Appropriate ICD-therapy and death occurred in 106(32%) and 114(34%) patients respectively. Rates of ICD generator replacement were 62% regardless of ICD-therapy. The multivariable model showed significant relationships between ANP > median (adjusted HR 1.73[95% CI 1.04-2.86]) and ADM > median (HR 0.53 [95% CI 0.32-0.89]) but not aldosterone, and ICD-therapy. The Fine and Gray analysis accounting mortality as a competing risk showed similar results.
CONCLUSIONS: The combination of ANP and ADM are independently associated with the risk of ICD-therapy in patients with an ICD that has never served, and may participate in stratifying patients who may benefit most from ICD generator replacement.